Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | HTR2B | P41595 | 3/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29845081 | 0.89 | BRD4 (0.38) | HTR2AHTR2CHTR2BADAM17ADAMTS5 | |
| SCHEMBL23217015 | 0.87 | HTR2A (0.36) | HTR2AHTR2CHTR2BADAM17ADAMTS5 | |
| SCHEMBL23217128 | 0.87 | HTR2A (0.34) | HTR2AHTR2CHTR2BADAM17ADAMTS5 | |
| SCHEMBL23227396 | 0.77 | BRD4 (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL23227397 | 0.77 | BRD4 (0.38) | HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL23217322 | 0.74 | HTR2C (0.41) | HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL23217560 | 0.73 | HTR2A (0.42) | HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL23217767 | 0.69 | HTR2A (0.43) | HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL23217507 | 0.69 | HTR2A (0.43) | HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL29845074 | 0.68 | HTR2A (0.43) | HTR2AHTR2CHTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049231-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-02-16 | — | — | US | disclosed |
| EP-4041405-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021071832-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049231-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNB1, KCNJ2, KCNB2 | HTR2A 1799/4885HTR2C 1162/4885HTR2B 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.